Home > Insider Trading > Filing (0001140361-21-033275)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1104506	Insmed Inc	INSM	Pharmaceutical Preparations (2834)	541972729

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1402051	William Lewis	700 Us Highway 202/206 Bridgewater NJ 08807	Chair And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-30	96,614	$3.40	298,833	No	4	M	Direct
Common Stock	Disposition	2021-09-30	83,307	$27.32	215,526	No	4	S	Direct
Common Stock	Disposition	2021-09-30	13,307	$27.64	202,219	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-09-30	96,614	$0.00	96,614	$3.40

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
3,386		2022-09-10	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Includes 748 shares acquired through the Company's 2018 Employee Stock Purchase Plan.
This is the weighted average sales price representing 83,307 shares sold at prices ranging from $26.60 to $27.59 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
This is the weighted average sales price representing 13,307 shares sold at prices ranging from $27.60 to $27.74 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.